Kaplan-Meier plots in (A, B) intent-to-treat and (C, D) biomarker-evaluable populations of (A, C) progression-free and (B, D) overall survival (generated using survival R package23). Dashed lines indicate medians. Bevacizumab refers to bevacizumab arm of AVAglio (bevacizumab plus radiotherapy plus temozolomide); placebo refers to placebo arm (placebo plus radiotherapy plus temozolomide). HR, hazard ratio.